UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________

FORM 8-K

______________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 149, 2026

_________________________________________________

QUANTERIX CORPORATION

(Exact name of registrant as specified in its charter)

_________________________________________________


Delaware	001-38319	20-8957988
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


900 Middlesex Turnpike
Billerica, MA			01821
(Address of principal executive offices)			(Zip Code)

(617) 301-9400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading symbol(s):

Name of each exchange on which

registered:

Common Stock, $0.001 par value per share

QTRX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnThe ~~May~~Board ~~14,~~of ~~2026,~~Directors ~~Anthony~~of ~~Catalano~~Quanterix ~~was~~Corporation (the “Company”) has appointed Jason Faessler as the Chief ~~Operating~~Financial Officer and Treasurer of ~~Quanterix~~the ~~Corporation~~Company. He (is expected to commence employment with the “Company”) on June 22, 2026.

Mr. ~~Catalano~~Faessler mostly recently was employed by ~~Flagship~~Brucker ~~Pioneering,~~Corporation ~~Inc.~~ as Senior Vice of President ~~Real~~of ~~Estate~~Finance, ~~and~~leading ~~Asset~~global ~~Management~~FP&A ~~from~~and ~~September~~the ~~2025~~Americas tofinance ~~May 2026~~organization. ~~Prior~~His toresponsibilities ~~Flagship~~have ~~Pioneering~~included strategic planning, ~~from~~operational ~~July~~finance ~~2025~~and tocapital ~~August~~decision-making. Before ~~2025~~that, he was ~~employed~~Senior byDirector ~~the~~of ~~Company,~~Finance ~~following~~at ~~the~~Parexel ~~Company’s~~Corporation ~~acquisition~~from ofApril ~~Akoya~~2018 ~~Biosciences,~~to ~~Inc.~~December ~~(“Akoya”). Mr.~~2018 ~~Catalano~~and ~~was~~Director ~~the Senior Vice President~~ of ~~Operations~~Finance at ~~Akoya~~Parexel from ~~April~~November ~~2023~~2015 to ~~July~~April ~~2025. He~~2018, ~~was~~where ~~the~~he ~~Senior~~led ~~Vice~~its ~~President~~early- ofand ~~Operations~~late-phase &clinical ~~Development~~divisions, ~~with~~driving ~~Bruker~~growth ~~Cellular~~and ~~Analysis,~~profitability ~~Inc.~~across ~~from~~both ~~June~~businesses. Prior ~~2021~~ to ~~April~~Parexel, ~~2023~~Mr. ~~and~~Faessler ~~the~~worked ~~Senior~~as Director of Finance and Sales Operations ~~with~~at ~~Revvity~~Harvard Business Publishing and held several financial planning, ~~Inc.~~analysis ~~from~~and ~~2010~~operation toroles ~~May~~at ~~2021~~EMC Corporation. Mr. ~~Catalano~~Faessler earned an MSMBA infrom ~~Chemistry~~the ~~from~~F.W. ~~Brandeis~~Olin ~~University~~Graduate ~~and~~School aof BSBusiness inat ~~Chemistry~~Babson College and a BA from the University of Massachusetts ~~at Lowell~~Boston.

The Company has entered into an employment agreement dated May 31, 2026 with Mr. ~~Catalano~~Faessler (the “Employment Agreement”) in connection with his appointment as Chief ~~Operating~~Financial Officer and Treasurer. The Employment Agreement provides for an initial annualized base salary of $~~400~~475,000, a cash sign-on bonus of $50200,000, and eligibility for an annual performance bonus with an annual bonus target of up to 50% of Mr. ~~Catalano~~Faessler’s base salary.

In connection with his appointment, Mr. ~~Catalano~~Faessler also ~~received~~will receive a long-term equity incentive award consisting of restricted stock units (RSUs) covering shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), equivalent to ~~0.30~~three-tenths of one percent (0.30%) of the shares of Common Stock outstanding on his start date. The RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. ~~Catalano~~Faessler’s start date.

If Mr. ~~Catalano~~Faessler’s employment is terminated by the Company without Cause (as defined in the Employment Agreement) or he resigns for Good Reason (as defined in the Employment Agreement), then he will receive continued payment of his base salary for ~~six~~12 months (the “Severance Period”), payment of an amount equal to his annual target bonus for the year of termination, pro-rated as of the date of termination, and subsidized health benefits during the Severance Period. If Mr. ~~Catalano~~Faessler’s employment is terminated by the Company without Cause or he resigns for Good Reason in connection with a Change-in-Control (as defined in the Employment Agreement), then ~~the~~he ~~Severance~~will ~~Period~~receive ~~will~~continued bepayment ~~extended~~of tohis ~~nine~~base salary for 12 months, payment of an amount equal to his annual target bonus for the year of termination, subsidized health benefits during the Severance Period, and all of his outstanding but unvested equity awards ~~subject to time-based vesting~~ will also become fully vested. Receipt of the foregoing termination benefits will be subject to Mr. ~~Catalano~~Faessler’s execution of a separation agreement, including certain restrictive covenants and a general release of all claims, in a form acceptable to the Company.

A copy of the Employment Agreement is filed as Exhibit 10.1 and is incorporated herein by reference.

Except for the Employment Agreement, there are no arrangements or understandings between Mr. ~~Catalano~~Faessler and any other person pursuant to which Mr. ~~Catalano~~Faessler was appointed as an officer. There are no family relationships between Mr. ~~Catalano~~Faessler and any director, director nominee or executive officer of the Company. There are no transactions to which the Company is a party and in which Mr. ~~Catalano~~Faessler has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K.

~~Michael~~Item ~~Miller,~~7.01 Regulation ~~formerly~~FD ~~the Chief Operating Officer of the Company, has transitioned to a new role as the Chief Technology and Products Officer of the Company~~Disclosure.

On June 9, 2026, the Company issued a press release, which announced the appointment of Mr. Faessler as Chief Financial Officer and Treasurer of the Company (the “Release”). A copy of the Release is attached as Exhibit 99.1 and incorporated herein by reference.

The information contained or incorporated in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

ExhibitNo.						Description
10.1						Employment Agreement ~~dated~~by ~~April~~and ~~30, 2026~~ between ~~Anthony~~the ~~Catalano~~Company and ~~the~~Jason ~~Company.~~Faessler
99.1						Press Release dated June 9, 2026
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 26, 2026	QUANTERIX CORPORATION
Date: June 9, 2026	QUANTERIX CORPORATION
	By:	/s/ Daniel S. Char
	Name:	Daniel S. Char
	Title:	Chief Legal Officer and Corporate Secretary

Filing Compare · Quanterix Corp